SEC Company Response from Immunovant, Inc. (IMVT) (CIK 0001764013) (IMVT) — Apr 8, 2020
Immunovant, Inc. (IMVT) (CIK 0001764013)
Date: April 8, 2020 · CIK: 0001764013 · Accession: 0001193125-20-100941
AI Filing Summary & Sentiment
File numbers found in text: 333-235975
Show Raw Text
CORRESP 1 filename1.htm CORRESP IMMUNOVANT, INC. 320 West 37th Street New York, NY 10018 April 8, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Immunovant, Inc. Registration Statement on Form S-1 File No. 333-235975 Acceleration Request Requested Date: April 9, 2020 Requested Time: 5:30 p.m., Eastern Daylight Time Ladies and Gentlemen: The undersigned registrant hereby requests that the staff of the U.S. Securities and Exchange Commission take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-235975) to become effective on April 9, 2020, at 5:30 p.m., Eastern Daylight Time, or as soon as practicable thereafter. Very truly yours, Immunovant, Inc. By: /s/ Peter Salzmann, M.D. Name: Peter Salzmann, M.D. Title: Chief Executive Officer cc: Pamela Yanchik Connealy, Immunovant, Inc. W. Bradford Middlekauff, Immunovant, Inc. Frank F. Rahmani, Cooley LLP John T. McKenna, Cooley LLP Alison A. Haggerty, Cooley LLP